Prosecution Insights
Last updated: May 29, 2026
Application No. 18/613,562

DENSLEY-PACKED ANALYTE LAYERS AND DETECTION METHODS

Non-Final OA §102§103
Filed
Mar 22, 2024
Priority
Sep 19, 2018 — provisional 62/733,525 +3 more
Examiner
TSAI, TSUNG YIN
Art Unit
2656
Tech Center
2600 — Communications
Assignee
Pacific Biosciences of California, Inc.
OA Round
1 (Non-Final)
82%
Grant Probability
Favorable
1-2
OA Rounds
7m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 82% — above average
82%
Career Allowance Rate
813 granted / 995 resolved
+19.7% vs TC avg
Moderate +11% lift
Without
With
+11.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
23 currently pending
Career history
1020
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
69.2%
+29.2% vs TC avg
§102
21.7%
-18.3% vs TC avg
§112
1.2%
-38.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 995 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of claims: 100-119 are pending below. Information Disclosure Statement The information disclosure statement (IDS) submitted on 8/19/2024, 3/14/2025, 6/4/2025 was filed and considered. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 100-118 are rejected under 35 U.S.C. 103 as being unpatentable over Staker et al (US 2018/0274028) in view of KLEIN et al (US 2017/0128365). Claim 100: Staker et al (US 2018/0274028) teaches the following subject matter: A method of controlling a center-to-center distance of two molecules on a substrate, wherein the substrate is coupled to an optical system, the method comprising (0176): (b) placing the two molecules onto a substrate (figure 10c and figure 11, paragraph 0176 detail various molecules on substrate); and (c) imaging the substrate; wherein the center-to-center distance of the two molecules in an image is less than a diffraction limit of the optical system (0176). Staker et al teaches all the subject matter above, but not the following: (a) treating the two molecules with an attractant or a repellant. KLEIN et al (US 2017/0128365) teaches the following subject matter: (a) treating the two molecules with an attractant or a repellant (0315 detail use of zwitterion as an electrostatic attraction). Staker et al and KLEIN et al are both in the field of image analysis, especially analysis of molecules on a substrate regarding measurement of centers (KLEIN et al detail in 0311) such that the combine outcome is predictable. Therefore it would have been obvious to one having ordinary skill before the effective filing date to modify Staker et al by KLEIN et al regarding attractant or repellant prove an effect highly effective lubrication hydrated charged groups as disclosed by KLEIN et al in 0312. Claim 101: KLEIN et al teach: The method of claim 100, wherein the repellant or the attractant comprises zwitterionic features (0315). Claim 102: KLEIN et al teach: The method of claim 100, wherein the repellant or the attractant comprises PEG (0443), a polysaccharide (0342), ampholine ampholytes, sulphobetaine, BSA, or any combination thereof. Claim 103: KLEIN et al teach: The method of claim 100, wherein the treating the two molecules with the attractant or the repellant comprises encasing the two molecules in a shell of the attractant or the repellant (0499 detail coverage/encasing). Claim 104: KLEIN et al teach: The method of claim 103, further comprising removing the shell of the two molecules prior to imaging the substrate (0458 detail rinsed in de-ionized water to remove; 0551 detail attributed to removal of residual intact). Claim 105: KLEIN et al teach: The method of claim 100, wherein the placing of the two molecules onto the substrate comprises dragging or pulling the two molecules (0315 detail use of zwitterion as an electrostatic attraction). Claim 106: Staker et al teach: The method of claim 100, further comprising exposing the two molecules placed onto the substrate to a gas-liquid interface such that the two molecules form a monolayer across the substrate (0115-0117 teaches air imaging system). Claim 107: Staker et al teach: The method of claim 106, wherein the gas-liquid interface is an air-water-interface (0115-0117 teaches air imaging system). Claim 108: Staker et al teach: The method of claim 100, wherein the two molecules comprise concatemers (0012). Claim 109: Staker et al teach: The method of claim 108, wherein the concatemers are hybridized to ssDNA hairs (0012; figure 2A and 0113; claim 2). Claim 110: Staker et al teach: The method of claim 108, wherein the attractant or the repellant increases an effective exclusion size of the concatemers without altering a size of the concatemers (figure 2A and 0113 detail overfill or project, as well as shorten segment, all view as altering size). Claim 111: Staker et al teach: The method of claim 108, wherein the concatemers comprise an actively extending end (figure 2A and 0113 detail project length). Claim 112: KLEIN et al teach: The method of claim 111, wherein the actively extended away is raised above the substrate (0563). Claim 113: Staker et al teach: The method of claim 100, wherein the two molecules are proteins or peptides (0099-0100). Claim 114: Staker et al teach: The method of claim 100, wherein the substrate comprises a patterned surface (0118-0119 detail patterned). Claim 115: Staker et al teach: The method of claim 100, wherein the substrate comprises an unpatterned surface (0192 detail non-patterned). Claim 116: Staker et al teach: The method of claim 100, wherein a plurality of molecules are disposed on the substrate at a density of about 1 to about 25 molecules per square micron (0023-0025). Claim 117: Staker et al teach: The method of claim 100, wherein the center-to-center distance between the two molecules is less than 400 nm (0119 and 0023). Claim 118: Staker et al teach: The method of claim 100, wherein the center-to-center distance between the two molecules is less than 300 nm (0119 and 0023). Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim 119 is rejected under 35 U.S.C. 102(a)(2) as being anticipated by Staker et al (US 2018/0274028) Claim 119: Staker et al (US 2018/0274028) anticipated following subject matter: A method of sequencing a plurality of analytes disposed at high density on a surface of a substrate, comprising: (a) performing a plurality of cycles of probe binding to a substrate comprising a surface, wherein the surface comprises a plurality of analytes immobilized adjacent to the surface in a monolayer due to, at least in part, a repellant of one or more adjacent analytes and a repellant of an analyte of the plurality of analytes, wherein a cycle of the plurality of cycles comprising (0010, 0017, 0031, 0049-0050): (i) contacting the plurality of analytes with a plurality of probes, a probe of the plurality of probes comprising a detectable label (0095-0096 detail binding efficient and probe; 0100-0101); and (ii) imaging a field of the surface with an optical system to detect an optical signal of a plurality of optical signals from each probe of the plurality of probes brought in contact with the plurality of analytes (0132-0133 detail binding with optical detection; 0151; 0173); (b) determining a peak location of an analyte of the plurality of analytes from each of the plurality of optical signals (0011 detail peak location determined; 0025-0026; 0031); and (c) identifying the analyte from the detectable label of the plurality of probes at the peak location across the plurality of cycles (0031, 0044-0049, specifically 0049 detail identifying densely packed analytes as well as each analyte; 0156 detail identify position/location). Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Marini et al (US 2006/0148104) Detection Of Ion Channel Or Receptor Activity – 0223: The distance between two particles (or other components) can be measured with respect to any fixed points of the particles (or components), e.g., between the centers of two spherical particles, the centers of mass of two irregularly shaped particles or components. 0346: concentration allows peptides to pack more tightly on the particles' surface, due to charge screening). The minimum peptide concentration required for complete surface coverage (computed for a 2 nM solution of 15 nm particles and counting 2 peptides per square nanometer, Any inquiry concerning this communication or earlier communications from the examiner should be directed to TSUNG-YIN TSAI whose telephone number is (571)270-1671. The examiner can normally be reached 7am-4pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bhavesh Mehta can be reached at (571) 272-7453. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TSUNG YIN TSAI/Primary Examiner, Art Unit 2656
Read full office action

Prosecution Timeline

Mar 22, 2024
Application Filed
Jun 17, 2024
Response after Non-Final Action
Apr 01, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12620465
LEARNING APPARATUS, LEARNING METHOD, TRAINED MODEL, AND PROGRAM
2y 9m to grant Granted May 05, 2026
Patent 12597118
IMAGE INSPECTION APPARATUS, IMAGE INSPECTION METHOD, AND IMAGE INSPECTION PROGRAM
4y 9m to grant Granted Apr 07, 2026
Patent 12597237
INFERENCE LEARNING DEVICE AND INFERENCE LEARNING METHOD
2y 7m to grant Granted Apr 07, 2026
Patent 12579797
VIDEO PROCESSING METHOD AND APPARATUS
3y 8m to grant Granted Mar 17, 2026
Patent 12573029
IMAGE ANNOTATION USING ONE OR MORE NEURAL NETWORKS
5y 10m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
82%
Grant Probability
93%
With Interview (+11.0%)
2y 10m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 995 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month